The IsKia trial findings presented at ASH 2023 are highlighted by Dr Fonseca.
This is a video synopsis/summary of a Post Conference Perspectives featuring Rafael Fonseca, MD.
The IsKia trial, presented for the first time, randomly assigned newly diagnosed multiple myeloma patients to 3 drugs (carfilzomib, lenalidomide, and dexamethasone) vs 4 drugs including the anti-CD38 antibody isatuximab. After 4 induction cycles, mobilization, transplant, and 4 consolidation cycles at the induction dose, minimal residual disease (MRD) was measured at various timepoints. The primary end point was post-consolidation MRD negativity by next generation sequencing (NGS).
With 151 patients per arm, baseline characteristics were balanced. Safety and study completion rates were similar between arms. The post-consolidation MRD negativity rate at 10-5 was 77% with isatuximab arm vs 67% without, meeting the primary end point. The more sensitive threshold of 10-6 showed lower rates of 67% vs 48%. Improvements in MRD were seen with continued therapy. Across subgroups, patients benefited, especially at 10-6. However, MRD negativity differences were most pronounced for high-risk cytogenetics patients, 77% vs 27%, indicating a continued need to improve outcomes in this population.
With good safety and increased MRD negativity rates favoring the 4-drug arm, the IsKia trial shows promise for adding isatuximab. Next steps are determining long-term survival data and potentially moving to the 10-6 MRD threshold. Currently, the choice between isatuximab vs daratumumab with these quadruplets is unclear. Both are reasonable options, pending drug access and approval considerations.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More